Target identification, validation and deconvolution

Target identification, validation and deconvolution

Leveraging advanced functional genomics and comprehensive in vitro/in vivo assay platforms, we collaborate closely with your team to generate proprietary, disease-relevant multi-omics datasets. These datasets are analysed using cutting-edge bioinformatics tools, offering a strong, innovative foundation for discovering and developing your assets, and helping ensure a data-driven and well-supported pathway to progress.

Cell partitioning and barcoding for single-cell sequencing are performed on a chip

Generation of the right model systems

We design and create customised cell models for target identification, validation and mode-of-action studies using CRISPR knock-out and knock-in, RNAi technologies and directed target overexpression. Parental cell lines are chosen to meet your project's specific needs. We work with various cell types, including verified immortalised and cancer cell lines, primary cells, induced pluripotent stem cell (iPSC)-derived cells and purified immune cells from whole blood. Co-culture, 2D culture and 3D culture formats are available.

Target screening

We conduct target screening campaigns using both unbiased and hypothesis-driven methods to better understand genotype-phenotype relationships, build disease-relevant models and elucidate mechanisms of action and biological pathways. We provide phenotypic and genetic screening of your chosen cell model (2D or 3D) in large-scale pooled or arrayed formats using custom or whole-genome targeting libraries (CRISPRn, CRISPRa, CRISPRi, perturb-seq and RNAi). Additionally, we employ advanced bioinformatics tools to support comprehensive data mining and hypothesis generation.

Target deconvolution

Phenotypic small-molecule screens help you discover novel therapeutic candidates. Identifying the direct drug target is crucial for efficient structure–activity relationship studies and rational drug design. Our target deconvolution services, including CRISPR-based screening and proteomics, help ensure precise identification of drug targets. We offer these methods individually or in combination, leveraging our proven expertise to support your drug discovery efforts.

Target Profiling

To assess the role of your targets in the proposed therapeutic context, we conduct a range of analyses, including transcriptomic and proteomic profiling, metabolomics and gene studies (knock-out, knock-down, and over-expression) both in vitro and in vivo. Additionally, we provide extensive bioinformatics support. For broad target profiling, we utilise immunohistochemistry (IHC) on tumor microarrays (TMAs), derived from a comprehensive collection of clinical samples. These arrays represent the most relevant tumor indications and include histopathological assessments.

Related topics & resources

Assays2Go and Xrays2Go systems for therapeutically interesting targets

Assays2Go platform

Discover how our Assays2Go services can enhance your drug discovery process.

Learn more

Illustrative visualization of immune cells, e.g. T cells, launching an attack on a cancer cell

High-throughput screening

With our unique expertise and state-of-the-art HTS equipment, we address a wide range of target classes.

Learn more

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

I agree to receive other communications from Nuvisan. In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

I have read and agree to Nuvisan's privacy policy. I consent to the processing of my personal data for the provision of content by Nuvisan only. I understand that I can revoke this consent at any time and exercise my rights as detailed in the Privacy Policy.*

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Email us

hello@nuvisan.com

Talk to us

+49 731 9840 0

Our locations

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com